Suppr超能文献

在各种调节剂存在的情况下,过氧化物酶体增殖物激活受体γ配体结合域的氢/氘交换(H/D-Ex)

Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.

作者信息

Hamuro Yoshitomo, Coales Stephen J, Morrow Jeffrey A, Molnar Kathleen S, Tuske Steven J, Southern Mark R, Griffin Patrick R

机构信息

ExSAR Corp., Monmouth Junction, New Jersey 08852, USA.

出版信息

Protein Sci. 2006 Aug;15(8):1883-92. doi: 10.1110/ps.062103006. Epub 2006 Jul 5.

Abstract

A nuclear receptor, peroxisome proliferator-activated receptor gamma (PPARgamma), is a ligand-dependent transcription factor involved in glucose homeostasis and adipocyte differentiation. PPARgamma is the molecular target of various natural and synthetic molecules, including anti-diabetic agents such as rosiglitazone. Amide hydrogen/deuterium-exchange (H/D-Ex), coupled with proteolysis and mass spectrometry, was applied to study the dynamics of the PPARgamma ligand binding domain (LBD) with or without molecules that modulate PPARgamma activity. The H/D-Ex patterns of ligand-free PPARgamma LBD show that the ligand binding pocket of LBD is significantly more dynamic than the rest of the LBD. Presumably, the binding pocket is intrinsically disordered in order to accommodate different ligands. The presence of two full agonists (rosiglitazone and GW1929), a partial agonist (nTZDpa), and a covalent antagonist (GW9662), changed the dynamics/conformation of PPARgamma LBD and slowed the H/D exchange rate in various regions of the protein. The full agonists slowed the H/D exchange more globally and to a greater extent than the partial agonist or the antagonist, indicating that the full agonist stabilizes the PPARgamma LBD more than the partial agonist or the antagonist. One interesting observation is that the two full agonists significantly stabilized helix 12 while the partial agonist and the antagonist did not perturb the H/D exchange of this region. The results showed that the change in protein dynamics induced by ligand binding may be an important factor for the activation of genes and that H/D-Ex is a useful method for analyzing the biological activity of drug leads.

摘要

核受体过氧化物酶体增殖物激活受体γ(PPARγ)是一种参与葡萄糖稳态和脂肪细胞分化的配体依赖性转录因子。PPARγ是各种天然和合成分子的分子靶点,包括罗格列酮等抗糖尿病药物。酰胺氢/氘交换(H/D-Ex)与蛋白水解和质谱联用,用于研究PPARγ配体结合域(LBD)在有或没有调节PPARγ活性的分子存在时的动力学。无配体的PPARγ LBD的H/D-Ex模式表明,LBD的配体结合口袋比LBD的其余部分具有更高的动态性。据推测,结合口袋本质上是无序的,以便容纳不同的配体。两种完全激动剂(罗格列酮和GW1929)、一种部分激动剂(nTZDpa)和一种共价拮抗剂(GW9662)的存在改变了PPARγ LBD的动力学/构象,并减缓了蛋白质各个区域的H/D交换速率。完全激动剂比部分激动剂或拮抗剂更全面、更显著地减缓了H/D交换,表明完全激动剂比部分激动剂或拮抗剂更能稳定PPARγ LBD。一个有趣的观察结果是,两种完全激动剂显著稳定了螺旋12,而部分激动剂和拮抗剂并未干扰该区域的H/D交换。结果表明,配体结合诱导的蛋白质动力学变化可能是基因激活的一个重要因素,并且H/D-Ex是分析药物先导物生物活性的一种有用方法。

相似文献

1
Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators.
Protein Sci. 2006 Aug;15(8):1883-92. doi: 10.1110/ps.062103006. Epub 2006 Jul 5.
2
Partial agonists activate PPARgamma using a helix 12 independent mechanism.
Structure. 2007 Oct;15(10):1258-71. doi: 10.1016/j.str.2007.07.014.
3
Mode of peroxisome proliferator-activated receptor γ activation by luteolin.
Mol Pharmacol. 2012 Jun;81(6):788-99. doi: 10.1124/mol.111.076216. Epub 2012 Mar 5.
4
A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist.
Anal Biochem. 2004 Dec 15;335(2):253-9. doi: 10.1016/j.ab.2004.09.004.
7
Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
J Mol Biol. 2009 Jan 9;385(1):188-99. doi: 10.1016/j.jmb.2008.10.039. Epub 2008 Oct 19.
10

引用本文的文献

1
Hallmarks of cellular senescence: biology, mechanisms, regulations.
Exp Mol Med. 2025 Jul 10. doi: 10.1038/s12276-025-01480-7.
4
Hydrogen Deuterium Exchange and other Mass Spectrometry-based Approaches for Epitope Mapping.
Front Anal Sci. 2023;3. doi: 10.3389/frans.2023.1118749. Epub 2023 May 18.
5
International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.
Pharmacol Rev. 2023 Nov;75(6):1233-1318. doi: 10.1124/pharmrev.121.000436. Epub 2023 Aug 16.
6
The PPAR Pocket: Renewed Opportunities for Drug Development.
PPAR Res. 2020 Jul 1;2020:9657380. doi: 10.1155/2020/9657380. eCollection 2020.
8
Recurrent activating mutations of PPARγ associated with luminal bladder tumors.
Nat Commun. 2019 Jan 16;10(1):253. doi: 10.1038/s41467-018-08157-y.
9
PPARγ in Complex with an Antagonist and Inverse Agonist: a Tumble and Trap Mechanism of the Activation Helix.
iScience. 2018 Feb 27;5:69-79. doi: 10.1016/j.isci.2018.06.012. Epub 2018 Jul 2.

本文引用的文献

1
Discovery and characterization of a substrate selective p38alpha inhibitor.
Biochemistry. 2004 Sep 21;43(37):11658-71. doi: 10.1021/bi0495073.
2
Mechanism of the nuclear receptor molecular switch.
Trends Biochem Sci. 2004 Jun;29(6):317-24. doi: 10.1016/j.tibs.2004.04.006.
3
Nuclear receptors: the evolution of diversity.
Sci STKE. 2004 Jan 20;2004(217):pe4. doi: 10.1126/stke.2172004pe4.
7
Protein structure change studied by hydrogen-deuterium exchange, functional labeling, and mass spectrometry.
Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7057-62. doi: 10.1073/pnas.1232301100. Epub 2003 May 28.
9
Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator.
Mol Endocrinol. 2003 Apr;17(4):662-76. doi: 10.1210/me.2002-0217. Epub 2003 Jan 16.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验